Clinical trial NCT00111748: UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
Official title: UARK 2005-01, A Phase III Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Multiple Myeloma
Keywords: Myeloma
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2005-05-25
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main goal of this study is to evaluate the effectiveness of the combination of these drugs, and whether they can be given safely together.

Detailed description: In this study, there will be two arms (or groups). One arm will receive Velcade, thalidomide, and dexamethasone (VTD), and the other arm will receive VTD with Adriamycin.

This study has the following specific goal:

To evaluate the efficacy and toxicity of two treatments in multiple myeloma patients, relapsing after at least one course of high-dose treatment and an autologous stem cell transplant, or after at least two lines of conventional chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Patients with relapsing multiple myeloma (MM)
* Patients must have adequate platelet count of \> 20,000 x 10\^9/L, independent of transfusions, unless it is due to massive myeloma infiltration.
* Anticipated life expectancy of at least 3 months
* Ejection fraction by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan performed within 60 days prior to registration; left ventricular ejection fraction (LVEF) \> 40% by ECHO or MUGA.
* Female patients of child bearing age are required to have a negative pregnancy test as indicated in thalidomide safety guidelines
* Patients must have a performance status of 0-2 based on Southwest Oncology Group (SWOG) criteria. Patients with a poor performance status (3-4), based solely on bone pain, will be eligible.
* All patients must be informed of the investigational nature of this study and must have signed an institutional review board (IRB)-approved informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

* Evidence of central nervous system (CNS) involvement
* Grade \> 2 peripheral neuropathy
* Hypersensitivity to Velcade, boron, or mannitol
* Recent (\< 6 months) myocardial infarction, cerebrovascular accident (CVA)/stroke, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias.
* Evidence of chronic obstructive or chronic restrictive pulmonary disease.
* Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years.
* Patients must not have significant co-morbid medical conditions or uncontrolled life threatening infection.
* Pregnant or nursing women. Women of child-bearing potential must have a negative pregnancy test documented within one week of registration. Women and men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the study treatment.

Primary outcomes:
measure: Evaluate the effectiveness of the combination of these drugs
timeFrame: 168 days
Secondary outcomes:
measure: Evaluate the efficacy and toxicity of two treatments in multiple myeloma patients, relapsing after at least one course of high-dose treatment and an autologous stem cell transplant
timeFrame: 168 days
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical sciences
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Klaus Hollmig, MD
role: PRINCIPAL_INVESTIGATOR
References: